Evidence map›Paper›PMID 37034217›Full record

ArticleAmerican journal of cancer research2023

The mechanism of long-chain acyl-CoA synthetase 3 in inhibiting cell proliferation, migration, and invasion in clear cell renal cell carcinoma.

Lin Zhang, Bo Wu, Dongwen Wang

Open access · greenAbstract read
In one paragraph

Article in American journal of cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Lin ZhangShanxi Medical University Taiyuan 030001, Shanxi, P. R. China.
Bo WuDepartment of Urology, First Hospital of Shanxi Medical University Taiyuan 030001, Shanxi, P. R. China.
Dongwen WangShanxi Medical University Taiyuan 030001, Shanxi, P. R. China.
Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Long-chain acyl-CoA synthases 3 (ACSL3) can activate long-chain fatty acids, which are often deregulated in tumors. However, the biological function of ACSL3 in clear cell renal cell carcinoma (ccRCC) is still unclear. In this research, the expression level, prognostic value, GO and KEGG functional enrichment analyses, genomic changes, clinical significance, immune infiltration of ACSL3 in ccRCC were comprehensively analysed. The expression levels of ACSL3 in ccRCC tissues were detected by quantitative reverse transcription-polymerase chain reaction (RT-qPCR), immunohistochemical staining (IHC), and Western blotting analysis. The proliferation, invasion, migration, apoptotic and lipid synthesis abilities of ccRCC cells were assessed using the cell counting kit (CCK-8), clone formation, scratch assay, Transwell assay, flow cytometry and Oil Red O assay, respectively. The results showed that ACSL3 was obviously downregulated in ccRCC and significantly associated with poor prognosis and clinicopathological factors of ccRCC patients. Additionally, the functional enrichment analysis indicated that ACSL3 was mainly involved in lipid synthesis and metabolism. The result of immune infiltration analysis proved that ACSL3 might regulate the tumor microenvironment of ccRCC. In addition, we demonstrated that overexpression of the ACSL3 could inhibit the proliferation, migration, and invasion of ccRCC cells, and promote apoptosis, reduce abnormal lipid accumulation. In conclusion, ACSL3 might be a novel ccRCC biomarker and the target for ccRCC tumor therapy.

Indexed as

ACSL3biomarkerclear cell renal cell carcinomaprognosistumor microenvironment

Identifiers

PMID37034217
PMCPMC10077045
OpenAlexW4363646819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.